MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Theralase Technologies Inc (OP:TLTFF)

0.1320 +0.0138 (+11.68%)
Streaming Delayed Price Updated: 3:58 PM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Theralase Technologies Inc

< Previous 1 2 3 Next >
News headline image
Theralase(R) Closes $CAN 1.2 Million Non-Brokered Private Placement
Via ACCESSWIRE
News headline image
Theralase(R) Provides Update on Phase II Bladder Cancer Clinical Study
Via ACCESSWIRE
News headline image
Theralase Release’s 3Q2023 Interim Financial Statements
Via ACCESSWIRE
News headline image
Theralase(R) Closes $CAN 1.17 Million Non-Brokered Private Placement
Via ACCESSWIRE
News headline image
Theralase(R) Commences Non-Brokered Private Placement and Termination of Previously Announced Financing
Via ACCESSWIRE
News headline image
Theralase(R) Optimizes Phase II Bladder Cancer Clinical Study
Via ACCESSWIRE
News headline image
Theralase(R) Provides Update on Bladder Cancer Clinical Study
Via ACCESSWIRE
News headline image
Theralase(R) Announces Brokered LIFE Financing
Via ACCESSWIRE
News headline image
Theralase(R) Files US Patent for Enhanced Immunotherapy
Via ACCESSWIRE
News headline image
Theralase(R) Demonstrates 8 Year Shelf Life of Lead Drug Ruvidar(TM)
Via ACCESSWIRE
News headline image
Theralase(R) Successfully Completes Non-GLP Toxicity Analysis for Brain Cancer
Via ACCESSWIRE
News headline image
Theralase(R) Grants Stock Options
Via ACCESSWIRE
News headline image
Theralase(R) Closes Private Placement Equity Financing
Via ACCESSWIRE
News headline image
Theralase Release’s 2Q2023 Interim Financial Statements
Via ACCESSWIRE
News headline image
Theralase(R) Closes Non-Brokered Private Placement Equity Financing
Via ACCESSWIRE
News headline image
Theralase(R) Announces Appointment of New Independent Director
Via ACCESSWIRE
News headline image
Theralase(R) Releases Corrected and Restated Press Release for 1Q2023 Interim Financial Statements
Via ACCESSWIRE
News headline image
Theralase(R) Releases 1Q2023 Interim Financial Statements
Via ACCESSWIRE
News headline image
Theralase(R) Appoints Roger DuMoulin-White as President and Chief Executive Officer
Via ACCESSWIRE
News headline image
Theralase Provides Update on Phase II Bladder Cancer Study
Via ACCESSWIRE
News headline image
Theralase Release FY2020 Audited Financial Statements
TORONTO, ON / ACCESSWIRE / April 28, 2021 / Theralase® Technologies Inc. ("Theralase" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and... 
From Theralase Technologies Inc.
Via AccessWire
News headline image
Theralase(R) Releases Quarterly Newsletter
TORONTO, ON / ACCESSWIRE / April 27, 2021 / Theralase® Technologies Inc. ("Theralase" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and... 
From Theralase Technologies Inc.
Via AccessWire
News headline image
Theralase Commences Collaborative Research with National Microbiology Laboratory for Development of Coronavirus Vaccine
TORONTO, ON / ACCESSWIRE / April 9, 2021 / Theralase® Technologies Inc. ("Theralase" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company focused on the research and... 
From Theralase Technologies Inc.
Via AccessWire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story